Summary:
3-ARM, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED,
RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102
AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS
PATIENTS WITH WALKING IMPAIRMENT
Qualified Participants Must:
• Male or female subjects between 18 and 70 years of age
•
Confirmed diagnosis of Multiple Sclerosis
Qualified Participants May Receive:
Compensation for time and travel